Cleared Traditional

VIOLA (K203307) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K203307 · Vascular Graft Solutions, Ltd. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2021
Decision
100d
Days
Class 2
Risk

K203307 is an FDA 510(k) clearance for the VIOLA. Classified as Clamp, Vascular (product code DXC), Class II - Special Controls.

Submitted by Vascular Graft Solutions, Ltd. (Tel Aviv, IL). The FDA issued a Cleared decision on February 17, 2021 after a review of 100 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4450 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Vascular Graft Solutions, Ltd. devices

Submission Details

510(k) Number K203307 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 09, 2020
Decision Date February 17, 2021
Days to Decision 100 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
25d faster than avg
Panel avg: 125d · This submission: 100d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DXC Clamp, Vascular
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.4450
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Consultant

Hogan Lovells US LLP
Janice Hogan

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - DXC Clamp, Vascular

All 39
Devices cleared under the same product code (DXC) and FDA review panel - the closest regulatory comparables to K203307.
SiteSeal SV
K210681 · Ensite Vascular · Apr 2021
MI DeTACH
K210006 · Biorep Technologies, Inc. · Mar 2021
V. Mueller Cosgrove Flex Clamps, Model Number-CV1033, CV1061, CV1133, CV1161, CV1186
K210324 · Carefusion 2200, Inc. · Mar 2021
VASOBand Vascular Compression Device
K203803 · Vasoinnovations, Inc. · Jan 2021
Patent Hemostasis Band (PH Band)
K201695 · Medical Ingenuities · Oct 2020
SiteSeal Femoral Compression Device
K192413 · Ensite Vacular, LLC · Mar 2020